ASH Annual Meeting and Exposition | Conference

Umbralisib/Ublituximab Plus Venetoclax Induces High Objective Response Rate in Relapsed/Refractory CLL

December 8th 2020

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in CLL

December 8th 2020

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

LOXO-305 Elicits Impressive Responses in Previously Treated CLL/SLL

December 8th 2020

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure

December 8th 2020

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

Liso-Cel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

Dr. Buske on the Results of the iNNOVATE Trial in Waldenström Macroglobulinemia

December 7th 2020

Christian Buske, MD, discusses the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Daratumumab Quadruplet Improves Hematologic CR Rate in AL Amyloidosis

December 7th 2020

December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

December 7th 2020

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Panobinostat/Subcutaneous Bortezomib Triplet at Higher Dosing Schedules Shows Favorable Outcomes in Relapsed/Refractory Myeloma

December 7th 2020

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.

Encouraging Efficacy Shown With Luspatercept in MDS/MPN-RS-T

December 7th 2020

December 7, 2020 — Findings from the MEDALIST trial demonstrated encouraging clinical efficacy, as well as a tolerable safety profile, with luspatercept among patients with myelodysplastic syndrome and myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

Survival Following Post–HCT Relapse in ALL Improves With Targeted Immunotherapies

December 7th 2020

December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.

All-Oral Ixazomib Triplet Improves PFS in Select Transplant-Ineligible Newly Diagnosed Myeloma

December 7th 2020

December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.

Daratumumab Combo Improved Response Rates for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma

December 7th 2020

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.

Ublituximab/Umbralisib Outperforms Chemoimmunotherapy in Patients with CLL

December 7th 2020

December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Negrin Shines Light on the Orca-T Story in GVHD

December 7th 2020

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

Glofitamab Demonstrates High CR Rate in Relapsed/Refractory NHL

December 7th 2020

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.

Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma

December 7th 2020

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

African-American Race: An Independent Predictor of Poor Survival in Younger Patients With AML?

December 7th 2020

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

Ide-Cel Delivers Clinically Meaningful HRQoL Benefits in Triple-Class Exposed Relapsed/Refractory Myeloma

December 6th 2020

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

CELMoD CC-92480/Dexamethasone Combo Shows Early Activity in Relapsed/Refractory Myeloma

December 6th 2020

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.